Impact of opportunistic disease on survival in patients with HIV infection

AIDS

Volumn 12, Issue 1, 1998, Pages 29-33

  Chaisson, Richard E ^a,b   Gallant, Joel E ^a   Keruly, Jeanne C ^a   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

CD4 lymphocytes; HIV; Natural history; Opportunistic infections; Survival

Indexed keywords

CD4 ANTIGEN;

ARTICLE; CANDIDIASIS; CAUSE OF DEATH; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; DEMENTIA; DISEASE ASSOCIATION; ESOPHAGITIS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONBIOLOGICAL MODEL; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; STATISTICS; SURVIVAL; TOXOPLASMOSIS; VIRUS PATHOGENESIS; WASTING SYNDROME;

ADULT; AIDS DEMENTIA COMPLEX; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV WASTING SYNDROME; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LYMPHOMA, AIDS-RELATED; MALE; PROPORTIONAL HAZARDS MODELS; RISK; SARCOMA, KAPOSI; SURVIVAL ANALYSIS;

EID: 0031983473     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199801000-00004     Document Type: Article

References (35)

1. Moore RD, Chaisson RE: Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996, 124:633-642.
2. Finkelstein DM, Williams PL, Molenberghs G, et al.: Patterns of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:38-45.
3. Selik RD, Chu SY, Ward JW: Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 1995,123:933-936.
4. Hoover DR, Saah AJ, Bacellar H, et al.: Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993, 329:1922-1926.
5. Saah AJ, Hoover DR, He Y, et al.: Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994, 7:287-295.
6. Chaisson RE, Keruly J, Richman DD, et al.: Pneumocystis prophylaxis and survival in patients with advanced HIV infection treated with zidovudine. Arch Intern Med 1992, 152:2009-2013.
7. Graham NM, Zeger SL, Park LP, et al.: Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS, Lancet 1991, 338:265-269.
8. Pierce MD, Crampton S, Henry D, et al.: A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996, 335:384-391.
9. Moore RD, Chaisson RE: Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium-complex in AIDS. AIDS 1995, 9:1337-1342.
10. Mellors J, Rinaldo Jr CR, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
11. Mellors J, Kinglsey LA, Rinaldo Jr CR, et al.: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
12. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
13. Perelson AS, Neumann AU, Markowitz M, et al.: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
14. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al.: The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:247-257.
15. Donovan RM, Bush CE, Markowilz NP, et al.: Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis 1996, 174:401-103.
16. Golletti D, Weissman D, Jackson RW, et al.: Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996, 157:1271-1278.
17. Stanley SK, Ostrowski MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222-1230.
18. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh-Kirk T: Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced HIV disease treated with zidovudine. Am Rev Respir Dis 1992, 146:285-289.
19. Chin DP, Reingold AL, Stone EN, et al.: The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients: a prospective study. J Infect Dis 1994, 170:578-584.
20. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE, Zidovudine Epidemiology Study Group: Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992, 166:1223-1227.
21. Chaisson RE, Keruly JC, Moore RD: Race, sex, drug use and the progression of HI V disease. N Engl J Med 1995, 333:751-756.
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
23. Cox DR: Regression models and life-tables. J R Stat Soc 1972, 34:187-220.
24. Liang K-Y, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.
25. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):1-19.
26. Mellors JW, Mun̄oz A, Giorgi JV, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
27. Galetto-Lacour A, Yerly S, Perneger TV, et al.: Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. J Infect Dis 1996, 173:1388-1393.
28. Katzenstein D, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nuclcoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996, 335:1091-1098.
29. Glesby MJ, Hoover DR, Farzadegan H, et al.: The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis 1996, 174:1332-1336.
30. Tasker S, O'Brien VV, Rossetti A, et al.: Effects of influenza vaccination in HIV-infected patients: a double-blinded, placebo-controlled trial. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract LB-11].
31. Fischl MA, Dickinson GM, La Voie L: Safely and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988, 259:1185-1189.
32. Powderly WG, Finkelstein D, Feinberg J, et al.: A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995, 332:700-705.
33. Bartlett JG: Protease inhibitors for HIV infection. Ann Intern Med 1996, 124:1086-1088.
34. Cameron B, Heath-Chiozzi M, Kravcik S, et al.: Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract LB6a].
35. 3. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract LB7].